April 26th 2024
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Highlights Role of BTK Inhibition in Treatment Landscape for CLL
August 18th 2020In an interview with Targeted Oncology, Jennifer Woyach, MD, discussed the current treatment landscape for patients with chronic lymphocytic leukemia and some of the latest research regarding the BTK inhibitors.
Read More
COVID-19 Severity in CLL Correlates With 3 Disease Characteristics
August 18th 2020The severity of coronavirus disease 2019 increases with age in patients with chronic lymphocytic leukemia. However, age and the existence of comorbidities may not impact death from COVID-19, according to results from a retrospective international study.
Read More
Ibrutinib Plus Umbralisib Induce Survival Benefit in Patients With CLL
August 17th 2020Matthew Davids, MD, MMSc, discusses the longer-term follow-up data from the phase 3 UNITY-CLL clinical trial, which evaluated umbralisib in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia.
Watch
Coutre Evaluates Treatment Options in Relapsed/Refractory CLL
August 13th 2020During a virtual Case Based Peer Perspectives event, Steven Coutre, MD, reviewed a case of a 53-year-old woman who first presented with elevated white blood cell count. The patient was later diagnosed with chronic lymphocytic leukemia.
Read More
FDA Grants Orphan Drug Designation to Cirmtuzumab in MCL and CLL
June 30th 2020"We are excited about cirmtuzumab’s potential for the treatment of patients with ROR1-expressing cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, HER2-negative breast cancer, and other solid tumors, and look forward to further advancing its development to benefit patients with significant unmet medical needs."
Read More
Discontinuation of Venetoclax Impacts Outcomes of Rituximab Combination in CLL
June 25th 2020In an interview with Targeted Oncology, Anthony Mato, MD, discussed the findings of venetoclax interruptions or discontinuations observed in patients with relapsed/refractory chronic lymphocytic leukemia who received the combination of venetoclax plus rituximab in the phase 3 MURANO study.
Read More
Complex Karyotype Strongly Associated With Shorter PFS in Chronic Lymphocytic Leukemia
June 25th 2020All patients with relapsed/refractory chronic lymphocytic leukemia should be evaluated for both complex karyotypes and del17p prior to initiating treatment, and all patients with complex karyotypes should be considered candidates for alternative combination therapy.
Read More
Ublituximab Plus Ibrutinib Induces Promises Responses in High-Risk Relapsed/Refractory CLL
June 11th 2020In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the findings for the combination of ublituximab plus ibrutinib as treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.
Read More
Cirmtuzumab Added to Ibrutinib Induces Responses in R/R MCL and CLL
June 6th 2020Compelling objective responses and safety results were demonstrated with the combination of cirmtuzumab and ibrutinib in cohorts of patients with mantle cell lymphoma and chronic lymphocytic leukemia, who were treated in the phase 1b/2 clinical trial.
Read More
Tumor Mutational Load Can Help Fine-Tune Prognoses in CLL
May 18th 2020Patients with chronic lymphocytic leukemia face uncertain futures, as clinicians can have a difficult time predicting whether and when a patient will need treatment. New research suggests tumor mutational load could be a helpful prognostic tool.
Read More